Investigational Drug Information for ADX-10061
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug ADX-10061?
ADX-10061 is an investigational drug.
There have been 17 clinical trials for ADX-10061.
The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2015.
The most common disease conditions in clinical trials are Narcolepsy, Syndrome, and Sleepiness. The leading clinical trial sponsors are Aldeyra Therapeutics, Inc., Jazz Pharmaceuticals, and ORA, Inc.
There are two US patents protecting this investigational drug and one hundred and seven international patents.
Summary for ADX-10061
| US Patents | 2 |
| International Patents | 107 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2015-05-01) |
| Vendors | 7 |
Recent Clinical Trials for ADX-10061
| Title | Sponsor | Phase |
|---|---|---|
| ADX-629 Therapy for Sjogren-Larsson Syndrome | William Rizzo, MD | Phase 1/Phase 2 |
| Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease | pharmtrace klinische Entwicklung GmbH | Phase 1 |
| Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease | Alzeca Biosciences, Inc. | Phase 1 |
Clinical Trial Summary for ADX-10061
Top disease conditions for ADX-10061
Top clinical trial sponsors for ADX-10061
US Patents for ADX-10061
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ADX-10061 | See Plans and Pricing | Pharmaceutical propylene glycol solvate compositions | McNeil-PPC, Inc. (Skillman, NJ) | See Plans and Pricing |
| ADX-10061 | See Plans and Pricing | Pharmaceutical co-crystal compositions | University of South Florida (Tampa, FL) The Regents of the University of Michigan (Ann Arbor, MI) Transform Pharmaceuticals, Inc. (Lexington, MA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ADX-10061
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ADX-10061 | Austria | AT550022 | 2022-02-15 | See Plans and Pricing |
| ADX-10061 | Australia | AU2003211021 | 2022-02-15 | See Plans and Pricing |
| ADX-10061 | Australia | AU2003213719 | 2022-02-15 | See Plans and Pricing |
| ADX-10061 | Australia | AU2003243354 | 2022-02-15 | See Plans and Pricing |
| ADX-10061 | Australia | AU2003243699 | 2022-02-15 | See Plans and Pricing |
| ADX-10061 | Australia | AU2003267231 | 2022-02-15 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
